Write for us!
A proposed law to end animal testing in UK medical research by 2035 is being sold as an act of compassion. But the real human cost of getting this wrong has been almost entirely absent from the debate — and it will fall hardest on those who can least afford it.
Herbie is a rabbit. He was bred for a laboratory, tattooed on his ear, and (as the story goes) rescued before his fate could be sealed. He has since become the face of one of the most emotionally compelling campaigns in recent British politics: a push to ban all animal experiments in medical research by 2035.
Herbie’s Law has attracted the backing of over 155 MPs and generated the kind of warm public support that makes politicians feel virtuous for signing on. It is easy to understand why. It is considerably harder to argue against a rabbit.
And yet the case for Herbie’s Law rests on a statistical sleight of hand so significant, and carries risks to patients so serious, that it deserves far more critical scrutiny than it has received. The campaign has constructed a narrative in which animal testing is both cruel and scientifically useless, a neat alignment of compassion and pragmatism that feels irresistible. The trouble is that the narrative is built on a false premise, and the policy it is driving could cost human lives.
The 92% myth
The centrepiece of Herbie’s Law’s scientific argument is a striking figure: that 92% of drugs found safe in animal experiments subsequently fail in human clinical trials. The implication, delivered with quiet persistence across every campaign briefing and parliamentary debate, is that animal testing is not merely cruel but ineffective, that it is failing to predict human outcomes, and that we are paying for that failure in wasted billions, wasted decades, and wasted animal lives.
This is a profound misreading of the data. Drug development failure is a multi-stage pipeline problem, and safety (the quality animal testing is actually designed to assess) accounts for only a fraction of the reasons drugs do not reach market. The dominant causes of clinical trial failure are:
- Insufficient efficacy: the drug does not work well enough in humans, or works inconsistently across patient populations.
- Pharmacokinetic issues: how the drug is metabolised differs from what was predicted.
- Commercial viability: the drug may work but not well enough to clear NICE cost-effectiveness thresholds, or a competitor has already captured the market.
To lump all 92% of failures together and attribute them to the inadequacy of animal models is to fundamentally misrepresent what animal testing is for. It is rather like blaming a building’s fire safety inspection because the building subsequently failed to sell. Animal testing is not designed to guarantee efficacy in Phase III trials. It is designed to identify compounds likely to cause serious harm before they are administered to human beings, and in that function, it has an extensive and serious record of success.
Decades of progress, unseen
The campaign’s visual language relies heavily on images of distressed primates, restraint devices, and open surgical procedures. These are real. They are also, in the main, historical. The photographs that appear on placards and campaign websites largely date from the 1970s, an era when the regulatory and ethical framework governing animal research was in its infancy.
The contemporary reality is considerably different. The 3Rs framework: Replace, Reduce, Refine – has transformed laboratory practice over four decades. Refinement has driven significant changes in housing, monitoring, anaesthesia, and the minimisation of distress. This is not merely a matter of institutional goodwill. Stressed animals produce unreliable data. The pharmaceutical industry has powerful scientific incentives to ensure the welfare of the animals they depend upon for valid results.
The laboratory mice that represent the vast majority of animal subjects in UK pharmaceutical research are purpose-bred, genetically modified strains maintained under controlled conditions with food, water, veterinary oversight, and regulated welfare standards. As for the primates whose images dominate campaign materials, they remain in use for specific and heavily regulated areas of research, including Parkinson’s disease, Alzheimer’s, and HIV vaccine development. They are housed and monitored under rigorous standards, both because legislation demands it and because they are extraordinarily valuable research investments.
The ‘alternatives’ are pipe dream solutions currently
Herbie’s Law’s legal architecture depends entirely on the premise that suitable alternatives either exist or will exist by 2035. This is, at present, a statement of hope rather than evidence. The technologies routinely cited, such as organ-on-a-chip systems, artificial intelligence modelling, computer simulation, three-dimensional cell cultures, are genuinely exciting. They represent real scientific progress, and responsible pharmaceutical research increasingly incorporates them where they have been validated.
The key phrase is “where they have been validated.” These technologies are currently capable of addressing specific, narrow questions in specific, well-characterised biological contexts. They cannot, at present, replicate what the whole-organism model provides: the cascading, systemic complexity of immune response, multi-organ interaction, metabolic variation across time, and the emergent effects of compounds on interconnected biological systems. No organ-on-a-chip, however sophisticated, is yet a body.
A legally mandated deadline does not accelerate fundamental science. It creates a compliance problem. If 2035 arrives and validated whole-system alternatives are not in place, which is the assessment of the majority of serious biomedical scientists, the result is not a humane transition. It is a regulatory vacuum. Drug candidates either cannot be properly tested or must be shipped to jurisdictions without equivalent restrictions. The latter outcome would likely result in worse conditions for laboratory animals globally, not better.
The Patients who don’t make the posters
The most serious consequence of Herbie’s Law and the one least present in public discussion, is what happens to patients if pharmaceutical development becomes substantially more expensive, slower, or more uncertain.
Drug development already operates on timelines of fifteen to twenty years from discovery to market, at costs that routinely exceed one billion pounds per approved medicine. Any significant disruption to the testing pipeline does not merely delay treatments. It alters the fundamental commercial calculation that determines which diseases get researched at all. Conditions affecting smaller patient populations, or populations in lower-income countries, or diseases that are difficult to price at a level that justifies development cost, are already chronically under-served. Raise the floor on development cost and the problem worsens.
The two-tier dynamic is not hypothetical. It is already present in the tension between what NICE will fund and what is available privately. Treatments for certain cancers, rare neurological conditions, and complex autoimmune diseases are already accessible to those who can pay and unavailable (or available only through extended waits and postcode lottery) to those who cannot. Anything that increases the cost base of pharmaceutical research pushes more treatments into the private tier and further from universal access.
The irony cuts deep. Herbie’s Law presents itself as a compassionate policy. Its likely consequence, if enacted on its current timeline, would be to make the UK pharmaceutical environment more hostile to the development of medicines for serious conditions, to price more treatments beyond the reach of NHS approval, and to burden those patients least equipped to fund private care with the greatest shortfall. The animals saved by the policy would be real. The patients harmed by it would be equally real. They simply do not appear on campaign literature.
The Oxford Precedent
This is not the first time British scientists and students have found themselves arguing against the tide of an emotionally dominant campaign. In 2006, a sixteen-year-old Oxford student named Laurie Pycroft watched an animal rights demonstration from a coffee shop window and founded Pro-Test; a counter-campaign that drew nearly a thousand people to march in support of the Oxford biomedical research facility that animal rights groups had repeatedly attempted to shut down through intimidation and, in some instances, violence.
The campaign against the Oxford lab, led by SPEAK, had previously succeeded in halting construction for over a year and driven Cambridge University to abandon plans for a primate research facility altogether. Pro-Test’s argument was simple and vindicated by subsequent events: that the Oxford facility would enable carefully regulated, welfare-conscious research producing treatments for Parkinson’s disease, Alzheimer’s, and infectious diseases. The facility was completed. The research continues. Pycroft received the Great Briton Award for his campaigning.
Herbie’s Law is a more sophisticated campaign than SPEAK, and it has found a more receptive parliamentary audience. But its structural argument has the same fundamental weakness: it asks the public to weigh the visible suffering of identifiable animals against the invisible, diffuse suffering of future patients who do not yet have names or faces. This is an argument that requires scientists, clinicians, and patient advocates to make with clarity, consistency, and courage.
In conclusion
None of this is an argument for complacency about animal welfare in research. The case for continuing to develop and validate alternatives, for enforcing and strengthening the 3Rs framework, and for scrutinising every instance of animal use to ensure it meets genuine necessity standards is entirely sound.
The case against Herbie’s Law is not a case against animal welfare. It is a case against bad policy: against a legally mandated deadline that the science cannot support, against a statistical argument that fundamentally misrepresents the evidence, and against a political process that has allowed emotional framing to crowd out a serious reckoning with the human cost of getting this wrong.
The patients who will need the drugs that do not get developed, who will be priced out of treatments made unaffordable by a more constrained research environment, who will find the NHS unable to fund medicines whose development was slowed by a policy designed to save rabbits – they deserve a voice in this conversation too.
Herbie’s story is moving. It was designed to be. But policy made from a single rabbit’s ear tattoo, built on a misread statistic, and implemented without validated alternatives in place is not compassion. It is sentiment dressed as legislation, and the people who pay the price will not be the ones who signed the petition. The irony is that the people signing these petitions are also the people who complain the loudest when the NHS refuses an overly expensive drug that extends life by a week or two, while also dragging the lives out on pets who are suffering an awful level of quality of life.
This article presents an opinion on the scientific and policy dimensions of Herbie’s Law. Statistics on drug trial failure rates drawn from published pharmaceutical pipeline analyses.
